News | May 26, 2025
Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
The company expects meaningful revenue contribution from this long-term agreement
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune
CRL shall invest another Rs. 200 crore for creation of additional beds
She has held senior positions at Coca-Cola in China and PepsiCo in India
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
